Envision Healthcare names new CEO, says surprise billing inquiry didn’t influence change
Radiology provider Envision Healthcare has found a new top exec just weeks after its longtime CEO vacated the position.
James Rechtin will assume leadership of the Nashville-based physician group, taking over Chris Holden, who spent 13 years at its helm. Congress is currently investigating Envision’s billing practices, however officials insisted the leadership change is not related to the inquiry.
“Despite previous media speculation, former CEO Chris Holden’s departure from Envision on February 5th was unrelated to surprise billing or the congressional inquiries surrounding surprise billing,” an Envision spokesperson told Radiology Business sister brand Health Exec. “Chris was with the company for 13 years, and Envision is grateful to Chris for his dedication and for building the strong leadership team that is taking the company forward today.”
Investor-owned Envision is one of the country’s largest multispecialty, facility-based provider groups, leading a team of more than 900 radiologists, along with numerous other provider types. The House Committee on Energy & Commerce is currently investigating Envision’s medical billing practices, while its owners have reportedly poured millions into the fight against legislation to address this issue. Private equity firm KKR completed its purchase of Envision last year for nearly $10 billion.
More than 90% of the physician firm’s business comes from treating patients in-network, the company said. Rechtin comes to Envision from DaVita Medical Group, where he previously served as regional president.
Read more about the announcement in Health Exec.
Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic.